3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
8
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
4
Endometrial Neoplasms
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Interventions
pembrolizumab
3
Cisplatin
3
Capecitabine
3
Trastuzumab
2
Paclitaxel
2
Irinotecan
2
Docetaxel
2
Carboplatin
2
tivozanib
1
tipifarnib
1
seribantumab
1
sargramostim
1
lenvatinib
1
entinostat
1
atezolizumab
1
Thalidomide
1
Psychiatric Rehabilitation
1
Peripheral Blood Stem Cell Transplantation
1
Oxaliplatin
1
Nivolumab
1
Mesna
1
Magnetic Resonance Spectroscopy
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Immunohistochemistry
1
Ifosfamide
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Gemcitabine
1
Fluorouracil
1
Filgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gallbladder Neoplasms
×
lenvatinib
×
Breast
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled